Cancer cells survive environmental stresses including DNA damage-inducing chemotherapy by entering cellular quiescence (G0). In our previous study, to elucidate how G0 leukemic cells become resistant to chemotherapy, we profiled them at the transcriptome, translatome and proteome levels. Here, we used these datasets to identify differentially expressed genes and find that IFN-stimulated genes are highly expressed in our G0 models of leukemic cells induced by AraC chemotherapy or serum-starvation. Mechanistically, upon induction of G0, STAT1 is phosphorylated on tyrosine 701, leading to transcription of IFN-stimulated genes. Importantly, our data reveal that activation of JNK and p38 MAPK is integral to STAT1 phosphorylation and expression of IFN-stimulated genes. Pharmacological inhibition of either JNK or p38 MAPK greatly reduced expression of IFN-stimulated genes as well as STAT1 phosphorylation, revealing a JNK-STAT1 pathway that regulates IFN-stimulated genes. While the expression of IFN-stimulated genes does not affect survival rates of patients with hematological malignancies and chemoresistance of G0 leukemic cells, we find that this JNK-STAT1 pathway enhances adherence of G0 leukemic cells. Consistently, inhibition of the JNK-STAT1 pathway dramatically reduced the number of adherent G0 cells. Interestingly, STAT1 is transiently phosphorylated within 24 hours of chemotherapy, leading to transcriptional expression of IFN-stimulated genes.
Introduction
Cellular quiescence (G0) can be induced under unfavorable conditions such as chemotherapy, serum-starvation, high confluency and contact inhibition (1) (2) (3) . In our previous study, G0 leukemic cells were induced by treatment of proliferating THP1 cells with AraC (cytosine arabinoside) chemotherapy or serum-starvation (4) . These G0 cells are resistant to subsequent AraC treatment and re-enter cell cycle under favorable conditions (4) (Fig. 1A) . To understand how G0 leukemic cells survive chemotherapy, their transcriptome, translatome (polysomeassociated RNAs) and proteome were systematically analyzed (4) . These studies revealed that gene expression in our G0 models of leukemic cells recapitulates that of in vivo chemoresistant leukemic models (4) . In this study, we used these datasets to identify differentially expressed genes in chemoresistant G0 leukemic cells. Surprisingly, we find that interferons (IFNs)stimulated genes were significantly increased in G0 leukemic cells. Although IFN-stimulated genes are traditionally believed to act as antiviral mediators (5) , recent studies showed that a subset of IFN-stimulated genes can promote survival of cancer cells under genotoxic stress (6) .
However, it is still unknown how IFN-stimulated genes are regulated and what their biological functions in chemoresistant leukemic cells are. In this study, we find that the expression of IFNstimulated genes is transcriptionally and transiently up-regulated via STAT1 phosphorylation.
Subsequently, they are translationally down-regulated in AraC resistant leukemic cells, correlating with expression of a translation inhibitor of IFN-stimulated genes, RPL13A.
Importantly, we demonstrate that the activation of JNK and p38 MAPK is essential for STAT1 phosphorylation and the expression of IFN-stimulated genes. Interestingly, the JNK-STAT1 pathway promotes cell adhesion of G0 leukemic cells.
Materials and Methods

Cell adhesion assay
A 24-well plate was coated with 5 μg/ml human fibronectin (BD Biosciences) for 2 hours at 37°C.
Proliferating and G0 THP1 cells were washed PBS and resuspended in media with 10% FBS.
Cells were added into a 24-well plate at a density of 1 × 10 5 cells / well and incubated for 2 hours at 37 °C in 5% CO2. The plate was washed with PBS to remove nonadherent cells and cells were stained with 0.2% crystal violet in 10% ethanol for 10 minutes. Microscopy images were taken and the number of adherent cells on the plate was determined.
Cell migration assay
Transwell chambers (8 μm pore, Corning) were pre-equilibrated with serum-free media for 1 hour. GFP-tagged THP1 or MCF7 cells (2 x 10 4 /chamber) were placed in the top chamber, and 700 μL of proliferating or serum-starved THP1 cells containing media, in the bottom chamber.
The bottom chamber with serum-starved THP1 cells was supplemented with 10% FBS as a control. The chambers were incubated at 37°C for 4 hours in 5% CO2. Cells on the upper surface of the filter were removed with a cotton swab. Migrated MCF7 cells on the underside of the filter were fixed in formaldehyde for 10 minutes and subsequently stained with 0.2% crystal violet. Migrated THP1 cells tagged with GFP were observed in the bottom chamber and visualized using a microscope. Microscope images were taken and the numbers of migrated cells were determined.
Results
IFN-stimulated genes are significantly increased in resistant G0 leukemic cells
To determine expression level of IFN-stimulated genes in G0 cells, gene set enrichment analysis (GSEA) (13) was conducted on our previously acquired transcriptome, translatome and proteome datasets of G0 leukemic cells that were induced by treatment of proliferating THP1 cells with 5 μM AraC or serum-starvation over time for up to 3-4 days. Importantly, both IFN-α and IFN-γ response genes are significantly up-regulated at transcriptome, transcriptome and proteome levels in G0 leukemic cells induced by AraC or serum-starvation, compared to proliferating cells ( Fig. 1B) . Furthermore, different cell types induced to G0 by serum-starvation in HFF, HEPG2 and U2OS cell lines but not in the MCF7 cell line, increase expression of IFNresponse genes. Chemotherapy or radiotherapy induces expression of a subset of IFNstimulated genes called the IFN-related DNA damage signature (IRDS) in breast cancer cells (14) . The expression level of this subset is significantly correlated with therapy resistance (14) in different types of solid tumors (14) (15) (16) (17) . We found that IRDS genes are also highly expressed in G0 cells ( Fig. 1B) including G0 leukemic cells (Fig. 1C ). To test if high expression of IFNstimulated genes in our G0 models of leukemic cells is conserved in in vivo resistant models of leukemia, we examined published transcriptome profiles of dormant leukemic cells (LRC) (18) and leukemia-initiating cells (LIC) (19) using the DAVID classification tool (20) . We found that interferon signaling pathway and immune response genes are significantly enriched in signature genes of LRC and LIC, respectively ( Fig. 1D ). These results confirm that our G0 leukemic cells are appropriate models to study how IFN-stimulated genes are regulated and their biological impact in resistant leukemia.
IFN-stimulated genes are transcriptionally induced by STAT1 phosphorylation in resistant G0 leukemic cells
We asked how IFN-stimulated genes are expressed in resistant G0 leukemic cells. Hosts cells release IFNs, a class of cytokines that trigger antiviral defense (5) . IFN binding to its receptors phosphorylates and activates the STAT transcription factor family via Janus kinase (JAK).
Activated STATs dimerize and translocate into the nucleus and initiate transcription of IFNstimulated genes (21) . To test if STAT proteins are activated, we examined them in a time course after G0 induction by Western blot analysis. We found that both AraC and serumstarvation induced STAT1 phosphorylation on tyrosine 701 in THP1 cells ( Fig. 2A ). These conditions specifically induce STAT1 activation as STAT3 or STAT5 were not phosphorylated (data are not shown). Interestingly, quantification of phosphorylated STAT1 in Fig. 2A shows that STAT1 was transiently phosphorylated at early times within 4-24 hours of serum-starvation or AraC treatment ( Fig. 2B) . In multiple leukemic cell lines, STAT1 was also phosphorylated with 24 hours of AraC treatment (Fig. 2C ). To investigate the localization of phosphorylated STAT1 in G0 leukemic cells, nuclear and cytoplasmic fractions were separated. As expected, phosphorylated STAT1 is distinctly localized to the nucleus one day after AraC treatment ( Fig.   2D ). To measure the effect of STAT1 phosphorylation on expression of IFN-stimulated genes, we analyzed the transcriptome of G0 leukemic cells upon inhibition of STAT1 phosphorylation. STAT1 phosphorylation was pharmacologically inhibited by the JAK inhibitor, ruxolitinib that is used to treat myelofibrosis (7) ( Fig. 2E ). We found that IFN-α, IFN-γ-stimulated genes including IRDS genes were significantly down-regulated upon ruxolitinib treatment, compared to vehicle ( Fig. 2F ) in AraC-treated cells. These data indicate that phosphorylation of STAT1 is responsible for the expression of IFN-stimulated genes.
Translational down-regulation of IFN-stimulated genes in AraC-resistant leukemic cells
In order to test if IFN-stimulated genes are translationally regulated in resistant G0 leukemic cells, we examined their expression at the transcriptome and translatome levels. Overall expression of IFN-α and IFN-γ stimulated genes in G0 leukemic cells induced by serumstarvation is similar between transcriptome and translatome datasets, indicating that the increase in these conditions is due to transient transcriptional regulation (Fig. 3A) . In contrast, in (24), is translationally attenuated in AraC-resistant cells (Fig. 3D ). These data suggest that increased RPLA13A correlates with and can contribute to translation repression of IFN-stimulated mRNAs via the GAIT complex.
Activation of JNK and p38 MAPK is required for STAT1 phosphorylation and expression of IFN-response genes
We demonstrated that STAT1 transcriptionally induces the expressed of IFN-stimulated genes ( Fig. 4A ). To study how phosphorylation of STAT1 is regulated in resistant G0 leukemic cells, we examined MAPK signaling pathways which are activated by various cellular stresses (25) ( Fig. 4A ). As shown in our previous study (4), p38 MAPK was rapidly phosphorylated and activated within two hours of AraC treatment (Fig. 4B ). Importantly, JNK MAPK was also quickly phosphorylated within few hours of AraC treatment, prior to STAT1 phosphorylation ( Fig. 4B ).
Based on the sequential phosphorylation of these MAPKs first and then STAT1, we hypothesized that activation of JNK or p38 MAPK is required for STAT1 phosphorylation ( 
IFN-stimulated genes do not promote survival of AraC-resistant leukemic cells and are not associated with overall survival rates of patients with hematological malignancies
We demonstrated that JNK or p38 MAPK phosphorylates STAT1, resulting in the expression of IFN-response genes (Fig. 4A) . These include IRDS genes that are known to be associated with therapy resistance in solid tumors. To investigate whether IFN-stimulated genes promote the survival of AraC-resistant cells, their expression was suppressed by JAK/STAT, JNK and p38 MAPK inhibitors, prior to AraC treatment, followed by measurement of cell viability and caspase activity to measure cell death. In our previous study, we found that p38 MAPK inhibition prior to AraC severely reduced the survival of AraC-resistant cells by destabilizing TNFα and DUSP1 mRNAs (4) . In this study, JNK inhibition with JNK-IN-8 protected leukemic cells from AraCmediated apoptosis in THP1 and MOLM13 cell lines, and did not affect the viability of untreated cells as a control (Fig. 5A ). This result suggests that in contrast to p38 MAPK which induces chemoresistance, JNK sensitizes leukemic cells to AraC treatment. On the other hand, STAT1 inhibition with ruxolitinib did not affect the viability of both AraC-treated and untreated leukemic cells ( Fig. 5A ). Together, these results suggest that even though activation of JNK, p38 MAPK and STAT1 is required for expression of IFN-stimulated genes, the expression of IFN-stimulated genes is not associated with therapy survival but likely with other cell biological roles in resistant cells. To test if the expression of IFN-stimulated genes affects the overall survival rates of patients with hematological malignancies, Kaplan-Meier analysis was conducted. We found that survival rates were not correlated with the expression level of IFN-stimulated genes in datasets of patients with AML, CML and lymphoma (Fig.5B) , consistent with no effect of STAT1 inhibition on survival of AraC-treated cells (Fig. 5A) . These data suggest that IFN-stimulated genes can promote therapy-resistance only in specific cancers rather than in hematological malignancies.
Resistant G0 leukemic cells show increased cell adhesion and induction of cell migration
Cell adherence and induction of cell migration play important roles in cancer invasion and metastasis (26) . To measure these functions in G0 leukemic cells, we used fibronectin-coated wells (27) and transwell assays (28) (Fig. 6A-B) . Interestingly, we found that G0 leukemic cells were more adherent on fibronectin-coated plates than proliferating leukemic cells (Fig. 6A ). In addition, the conditioned media from G0 leukemic cells enhanced migration of co-cultured GFP-THP1 and MCF7 cells (Fig. 6B ). These data are consistent with the translatome and proteome datasets of G0 leukemic cells and other G0 cells that reveal significant increase in expression of cell adhesion and cell migration inducing genes.
The JNK-STAT1 signaling pathway promotes cell adhesion of resistant G0 leukemic cells
To measure the effect of the JNK-STAT1 pathway on adhesion and induction of migration of resistant G0 leukemic cells, the JNK-STAT1 pathway was suppressed by JNK or STAT1 inhibition. Importantly, JNK inhibition greatly reduced the number of G0 leukemic cells that were attached on fibronectin-coated plates (Fig. 6C) . When STAT1 and IFN-stimulated genes were directly inhibited by ruxolitinib, the number of adherent cells also decreased ( Fig. 6D) , consistent with the decreased cell adhesion observed with upstream inhibition of JNK (Fig. 6C ). However, STAT1 inhibition did not affect migration of co-cultured GFP-tagged THP1 and MCF7 cells ( Fig.   6E ). Together, these results suggest that the JNK-STAT1 pathway promote adherence of G0 leukemic cells. These data correspond to increased expression of cell adhesion genes in G0 leukemic cells (Fig. 6F) . The immunoglobulin superfamily is a group of cell surface proteins that are involved in the adhesion or recognition of cells (29) . Interestingly, we found that a subset of the immunoglobulin superfamily and cell adhesion genes that are highly expressed in G0 leukemic cells, are suppressed upon STAT1 inhibition (Fig. 6F) , indicating that these genes are targets of IFN-STAT1 pathway, and can contribute to cell adhesion in resistant G0 leukemic cells.
Discussion
In response to viral infection, host cells express IFN-stimulated genes to exert antiviral functions (5) . In this study, we reveal that AraC chemotherapy and serum-starvation treatment induces IFN-stimulated genes at transcriptome, translatome and proteome levels in leukemic cells ( Fig.1B) . Furthermore, gene signatures of in vivo resistant models of leukemia such as LRC (18) and LIC (19) include IFN-stimulated and immune response genes (Fig. 1D ), indicating the clinical relevance of our observation. We further show that IFN-stimulated genes are transcriptionally induced by STAT1 phosphorylation in G0 leukemic cells (Fig. 2) .
Our data revealed that AraC treatment or serum-starvation induced phosphorylation of STAT1 ( Fig. 2A) . Phosphorylation on tyrosine 701 and serine 727 of STAT1 is involved in its activation (30) . IFN binding to its receptor leads to tyrosine 701 phosphorylation of STAT1 by JAK, which is required for its localization to nucleus and enables its roles in transcription. In addition, phosphorylation on serine 727 is required for full transcriptional activation of STAT1 in IFN signaling (31) . Our data reveal that AraC treatment or serum-starvation activates both p38 MAPK and JNK (Fig. 4B) (4) . Apart from the known effect of p38 MAPK on phosphorylation of serine 727 (33, 34) , we find that both p38 MAPK and JNK control phosphorylation of STAT1 on tyrosine 701 (Fig. 4C) , permitting full activation of STAT1-mediated transcription of IFNstimulated genes in G0 leukemic cells.
Although previous studies have shown how phosphorylation of STAT protein is regulated by
MAPK signaling in response to LPS, UV and TNFα (32), regulation of STAT and IFN is poorly understood in chemotherapy-induced G0 leukemic cells. Activation of p38 MAPK was shown to enhance STAT1 phosphorylation upon UV and LPS treatment (33, 34) . In non-leukemic cells, activation of JNK with UV irradiation or its upstream kinase MKK7 has been shown to significantly block STAT3 tyrosine phosphorylation and transcription of IFN-stimulated genes (35) ; however, in G0 leukemic cells, AraC treatment activated JNK but did not induce any changes in STAT3 phosphorylation (data not shown). In chemoresistant G0 leukemic cells, our data reveal that both JNK and p38 MAPK play an essential role in STAT1 phosphorylation and transcriptional expression of IFN-stimulated genes. Pharmacological inhibition of JNK or p38 MAPK drastically inhibited STAT1 phosphorylation and expression of IFN-stimulated genes (Fig.   4C-E) . These data suggest that the effect of MAPKs on activation of STAT proteins is specific for cell type and environmental stimuli.
Interestingly, we observed that IFN-stimulated genes that are transcriptionally induced by STAT1 phosphorylation upon early times of AraC treatment, are subsequently, at later times, translationally down-regulated. RPL13A can translationally decrease expression of a subset of IFN-stimulated genes (24) ; consistently, we find that RPL13A is significantly increased in AraCresistant cells (Fig. 3B-C) . Correspondingly, RPL13A targets including VEGFA (Fig. 3D ) and other IFN-stimulated genes are translationally reduced.
Our findings reveal that resistant G0 leukemic cells are more adherent and induce migration of neighboring cells (Fig. 6A-B ). We demonstrate that the JNK-STAT1 pathway is responsible for adherence of resistant G0 leukemic cells but does not underlie the increased induction of cell migration observed in resistant G0 leukemic cells ( Fig. 6C-E) . AML cells express cell adhesion molecules on their surface to interact with the bone marrow microenvironment (36, 37) . This interaction is advantageous for tumor persistence as it protects leukemic cells from chemotherapy and promotes disease relapse (36, 37) . Therefore, although inhibitors of STAT1 or JNK do not increase chemosensitivity in vitro (Fig. 5A ), inhibiting this JNK-STAT1 pathway could therapeutically target drug-resistant leukemic cells in vivo by reducing their cell adhesion ability; and thereby, curb their interaction with the bone marrow niche, which is critical for tumor survival. In conclusion, our study reveals that a JNK-STAT1 pathway controls expression of IFN-stimulated genes and promotes cell adhesion in G0 leukemic cells.
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